Document Detail


Selective inhibition of platelet cyclooxygenase with controlled release, low-dose aspirin.
MedLine Citation:
PMID:  2126726     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The hypothesis that slow administration of low doses of aspirin may selectively inhibit platelet cyclooxygenase and thromboxane A2 formation was evaluated using controlled release aspirin formulations. In the first study, doses of either 50, 100, 325 and 1,300 mg of these formulations and 300 mg soluble aspirin were ingested daily by healthy volunteers for one week. In the second study, doses of 5, 10, 25 and 50 mg controlled release aspirin, 50 mg soluble aspirin and 100 mg aspirin and glycine formulation were ingested daily for ten days. Platelet function and urinary prostaglandin production were assessed immediately before and on the seventh day of dosing in both studies and in the second study, repeated on the tenth day of dosing. Platelet function and serum thromboxane B2 production were fully inhibited by all formulations of 50 mg aspirin and above, but not by doses of controlled release aspirin below 50 mg doses. The excretion of urinary 6-keto-PGF1 alpha (a major metabolite of prostacyclin) was significantly reduced at controlled release aspirin doses above 100 mg and at all doses of rapidly absorbed aspirin tested. As no significant reduction in the urinary 6-keto-PGF1 alpha production was observed at doses of controlled release aspirin of 50 and 100 mg and below, it appeared that these doses did not inhibit the systemic vascular cyclooxygenase. These data are consistent with a selective inhibition of platelet function by daily doses of 50 and 100 mg of the controlled release formulation of aspirin.
Authors:
J H Vial; L J McLeod; M S Roberts; P R Seville
Related Documents :
11510496 - Suppressive effect of aspirin on chromosome aberration induced by mitomycin c in mice.
11683686 - Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagi...
3949446 - S.e.m. study ii: protective effect of ranitidine against gastric and duodenal lesions i...
19110786 - Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with in...
11328736 - Doxil-induced chemomyectomy: effectiveness for permanent removal of orbicularis oculi m...
9610696 - A phase i clinical and pharmacologic study of a carboplatin and irinotecan regimen comb...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Australian and New Zealand journal of medicine     Volume:  20     ISSN:  0004-8291     ISO Abbreviation:  Aust N Z J Med     Publication Date:  1990 Oct 
Date Detail:
Created Date:  1991-03-20     Completed Date:  1991-03-20     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  1264322     Medline TA:  Aust N Z J Med     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  652-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Tasmania, Hobart, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Ketoprostaglandin F1 alpha / urine
Aspirin / administration & dosage*,  pharmacokinetics,  pharmacology
Blood Platelets / enzymology*,  metabolism
Delayed-Action Preparations
Female
Humans
Male
Platelet Aggregation / drug effects
Platelet Aggregation Inhibitors / pharmacology
Prostaglandin-Endoperoxide Synthases / blood*
Thromboxane B2 / blood,  urine
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 54397-85-2/Thromboxane B2; 58962-34-8/6-Ketoprostaglandin F1 alpha; EC 1.14.99.1/Prostaglandin-Endoperoxide Synthases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A rare complication of parenteral fat nutrition in a child
Next Document:  Clinical benefit of transdermal glyceryl trinitrate when used with an eight hour patch-free period.